The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study

被引:8
作者
Abu-Tineh, Mohammad [1 ]
Ali, Elrazi A. [2 ]
Alshurafa, Awni [1 ]
Nashwan, Abdulqadir J. [3 ]
Albsheer, Khalid [4 ]
Ahmed, Ashraf [5 ]
Hailan, Yousef [5 ]
Rozi, Waail [5 ]
Aljaloudi, Esraa [6 ]
Yassin, Mohamed A. [1 ]
机构
[1] Natl Ctr Canc Care & Res, Dept Med Oncol, Hematol & BMT Sect, Doha, Qatar
[2] One Brooklyn Hlth Interfaith Med Ctr, Internal Med, Brooklyn, NY USA
[3] Hamad Med Corp, Nursing Dept, Doha, Qatar
[4] Hamad Gen Hosp, Internal Med, Doha, Qatar
[5] Hamad Med Corp, Internal Med, Doha, Qatar
[6] Hamad Med Corp, Dept Family Med, Doha, Qatar
关键词
fatherhood; chronic myeloid leukemia; cml; tyrosine kinase inhibitors; tkis; IMATINIB MESYLATE; PREGNANCY;
D O I
10.7759/cureus.33407
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Multiple studies have demonstrated that tyrosine kinase inhibitors (TKIs) exert a significant extent of control over chronic myeloid leukemia (CML), as evidenced by studies such as the population-based Swedish CML registry, which found that patients reaching age 70 had a relative survival rate close to one when compared to the general population. Consequently, new perspectives on the safety of treatments have emerged, particularly in the context of their impact on fatherhood in men. According to the authors, this is the first study to examine the effect of TKIs on fatherhood in CML patients. Methods: A single-center, mixed-design study (retrospective data review and phone interviews) was conducted with CML male patients in the chronic or accelerated phase, evaluating the effect of imatinib, dasatinib, and nilotinib on their fatherhood, irrespective of whether they were administered as a first, second, or third line of treatment. Results: The study included interviews with 150 patients. Included were 27 patients. The average age was approximately 44.5 years. One hundred percent of the patients were in the chronic phase. The median age at first conception following TKI therapy was 36, and the median duration of TKI therapy was approximately seven years. The total number of offspring was 49; 98% were born at term and had a normal birth weight. No reports of stillbirths, fetal deaths, or congenital malformations were made. All the offspring grew and developed normally. No CML-related cancers were reported in any of the newborns. Conclusion: Around 98% of male CML patients receiving imatinib, dasatinib, or nilotinib did not experience a negative impact on their fatherhood or the health of their children. However, improved education for patients beginning treatment with TKIs addresses the potential psychological worry of having an unfavorable effect on their fertility or offspring, which may increase medication adherence.
引用
收藏
页数:7
相关论文
共 31 条
[1]   Tyrosine Kinase Inhibitors and Pregnancy [J].
Abruzzese, Elisabetta ;
Trawinska, Malgorzata Monika ;
Perrotti, Alessio Pio ;
De Fabritiis, Paolo .
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2014, 6 (01)
[2]   The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients with Chronic Myeloid Leukemia, a Single Institution Experience [J].
Abu-Tineh, Mohammad ;
Ali, Elrazi Awadelkarim A. ;
Alshurafa, Awni ;
Alhaj, Khalid ;
Hailan, Yousef ;
Kashgary, Waail Rozi ;
Nashwan, Abdulqadir Jeprel ;
Yassin, Mohamed A. .
BLOOD, 2021, 138
[3]  
Ali Elrazi, 2021, Acta Biomed, V92, pe2021193, DOI 10.23750/abm.v92i3.10796
[4]   Essential thrombocythemia with (type2) calreticulin presented as stuttering priapism case report and review of literature [J].
Ali, Elrazi Awadelkarim ;
Nashwan, Abdulqadir Jeprel ;
Yassin, Mohamed A. .
CLINICAL CASE REPORTS, 2021, 9 (01) :399-404
[5]  
[Anonymous], 2022, GLEEVEC IM MES
[6]   Pregnancy among patients with chronic myeloid leukemia treated with imatinib [J].
Ault, P ;
Kantarjian, H ;
O'Brien, S ;
Faderl, S ;
Beran, M ;
Rios, MB ;
Koller, C ;
Giles, F ;
Keating, M ;
Talpaz, M ;
Cortes, J .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1204-1208
[7]   Gynecologic cancer treatment and the impact of cancer-related infertility [J].
Carter, J ;
Rowland, K ;
Chi, D ;
Brown, C ;
Abu-Rustum, N ;
Castiel, M ;
Barakat, R .
GYNECOLOGIC ONCOLOGY, 2005, 97 (01) :90-95
[8]   Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase [J].
Chang, Xiaohui ;
Zhou, Lin ;
Chen, Xiaoxia ;
Xu, Baoli ;
Cheng, Yubin ;
Sun, Shujun ;
Fang, Meiyun ;
Xiang, Yang .
TARGETED ONCOLOGY, 2017, 12 (06) :827-832
[9]   Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study [J].
Conchon, Monika ;
Sanabani, Sabri S. ;
Bendit, Israel ;
Santos, Fernanda Maria ;
Serpa, Mariana ;
Dorliac-Llacer, Pedro Enrique .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2009, 2
[10]   Staging of chronic myeloid leukemia in the imatinib era - An evaluation of the World Health Organization proposal [J].
Cortes, JE ;
Talpaz, M ;
O'Brien, S ;
Faderl, S ;
Garcia-Manero, G ;
Ferrajoli, A ;
Verstovsek, S ;
Rios, MB ;
Shan, J ;
Kantarjian, HM .
CANCER, 2006, 106 (06) :1306-1315